Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Emerging ASX Gems Conference 2022
20 slides from Proteomics International Laboratories's conference presentation, Nov 4, 2022
Slide 1: ASX Release: Investor Presentation to the Emerging ASX Gems Conference
ASX Release 4 November 2022 ASX code: PIQ Investor Presentation to the Emerging ASX Gems Conference Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Managing Director Dr Richard Lipscombe to attendees of
Slide 2: Proteomics International Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Investor Presentation Emerging ASX Gems Conference 4 November 2022 Dr. Richard Lipscombe Managing Director
Slide 3: Disclaimer
Disclaimer ASX: PIQ ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associ
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ ASX:PIQ A medical technology company at the forefront of Corporate Snapshot – 31/10/2022 precision medicine and predictive diagnostics ASX code PIQ Share Price A$0.915 Diagnostics Shares on issue (+8.4m options) 115m PromarkerD Market Capitalisation
Slide 5: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 4
Slide 6: A new blood test for predicting diabetic kidney disease
ASX: PIQ ASX:PIQ A new blood test for predicting diabetic kidney disease 5
Slide 7: Problem & Solution
Problem & Solution ASX: PIQ ASX:PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the Roadblock onset of diabetic kidney disease The Problem • If unchecke
Slide 8: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ ASX:PIQ Blood sample drawn Biomarkers analysed Results analysed by Results and intervention PromarkerD Hub software plan delivered Sample is drawn at clinic Laboratory uses a standard Cloud based algorithm, the Clinician delivers results or path
Slide 9: PromarkerD – Route To Market
PromarkerD – Route To Market ASX: PIQ ASX:PIQ Diagnostic company / laboratory Laboratory conducts tests & submits raw Laboratory pays PIQ a royalty per license PromarkerDTM data to PromarkerD hub test Immunoassay kits PromarkerD Hub calculates ‘risk score’ manufactured and supplied and sends report
Slide 10: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ ASX:PIQ Further Global Potential in New Markets ▪ Employs the Promarker™️ technology platform to develop novel intellectual property The Promarker™️ Research ▪ Targeting new diagnostic tests in areas of significant unmet need Pipeline & Timeline ▪ Enormous markets and r
Slide 11: In Development: Endometriosis / Oesophageal Cancer
In Development: Endometriosis • Endometriosis is a common and painful disease where tissue that normally lines the uterus grows into other organs • Currently diagnosis takes an average of 7.5 years and requires invasive surgery (laparoscopy) • Affects 1 in 9 women and costs Australia over AU$10 bill
Slide 12: Value Inflection Points
Value Inflection Points ASX: PIQ ASX:PIQ Exceptional Global Share Price Catalysts FY23 Opportunity Milestone Dec Qtr ’22 1H CY23 Impact ➢ Disruptive, cutting-edge technology & PromarkerD proven in-house diagnostics platform Execution of Sonic Healthcare USA licence. Licensing Deals ➢ PromarkerD test
Slide 13: Contact
Contact ASX: PIQ ASX:PIQ Dr Richard Lipscombe Kyle Moss Managing Director Corporate Advisor T:+61 8 9389 1992 Euroz Hartleys E: enquiries@proteomicsinternational.com T:+61 9488 1400 www.proteomicsinternational.com E: kmoss@eurozhartleys.com Dirk van Dissel Investor Relations & Corporate Advisor Cand
Slide 14: Supplemental
Supplemental ASX: PIQ ASX:PIQ 13
Slide 15: Peer Comparison
Peer Comparison ASX: PIQ Market Share FY22 ASX:PIQ FY22 Net Stock Code Company Focus Capitalisation Price Revenue Profit/Loss Proteomics Predictive blood test for Diabetic Kidney Disease; simple, cost effective, pending launch in USA. International PIQ.ASX Pipeline of novel proteomics derived diagno
Slide 16: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), CA, MAICD, Non-Executive Chair ASX:PIQ Seasoned finance professional with over 30 years’ experience providing South & corporate advice to Boards of public and private companies. He was Co-Founder and MD of Torr
Slide 17: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ The PromarkerD predictive test is poised to roll-out in markets globally ASX:PIQ Enormous Market ✓ 537m adults have diabetes globally: 1-in-3 currently have diabetic kidney disease (DKD) Peer reviewed publications – Clinical & analytical validity proven (Sensitiv
Slide 18: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention How PromarkerDTM results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Annually •
Slide 19: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management ASX:PIQ Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney
Slide 20: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ ASX:PIQ 45% Diabetes incidence and Patent portfolio undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,491,800 Brazil BR112013006740 Granted 15,733,600 537M Canada 2811654 Granted 2,974,000 China ZL201180053583
Proteomics International Laboratories — Emerging ASX Gems Conference 2022 on 6ix